{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:38:03Z","timestamp":1787027883967,"version":"build-2736575974"},"reference-count":28,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:00:00Z","timestamp":1724457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University of Medicine and Pharmacy \u201cIuliu Ha\u021bieganu\u201d Cluj-Napoca"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CIMB"],"abstract":"<jats:p>Multiple myeloma, the disease characterized by the malignant proliferation of plasma cells that invades the bone marrow, produces osteolytic lesions and secretes monoclonal proteins. Several biomarkers have been shown to represent important tools in the pathogenesis of myeloma and offer insights into bone degradation and formation. The objectives of this current study were to assess the associations of modern biomarkers (TNF-\u03b1: tumor necrosis factor; IFN: Interferon; FreeRANKL: Free Receptor Activator for Nuclear Factor kappa B Ligand; RANKL: Receptor Activator for Nuclear Factor kappa B Ligand, Beta crosslaps, IL-6: Interleukin 6) with osteolytic lesions status after first-line treatment and to evaluate the correlations between modern and classical biomarkers (LDH: Lactate Dehydrogenase; VSH: Erythrocyte Sedimentation Rate; Hgb: Hemoglobin, Calcium, Albumin, B2microglobulin) stratified by osteolytic lesions status. A total of 35 patients diagnosed with multiple myeloma divided into two groups according to the osteolytic bone lesions, were studied: (1) unchanged status of osteolytic lesions and (2) changed status of osteolytic lesions. After fist-line treatment, we found a significant difference in Albumin (p = 0.0029) and Calcium levels (p = 0.0304), patients with a changed status in osteolytic lesions having higher values of Albumin and Calcium compared to those without changes in status of osteolytic lesions. After first-line treatment, decreased IL-6 values were significantly correlated with elevated values of Albumin (\u03c1 = \u22120.96, p = 0.0005) in the patients with changed status of osteolytic lesions. Post-treatment values of IFN showed a significant positive correlation with Hemoglobin (\u03c1 = 0.47, p = 0.0124), IL-6 (\u03c1 = 0.55, p = 0.0026) and TNF-alpha values (\u03c1 = 0.54, p = 0.0029). The results obtained from patients with unmodified lytic lesions identified a significant correlation between the biomarkers IL-6, Free RANKL, and IFN-beta with the classical marker LDH. This association highlights the involvement of these markers in promoting bone destruction and the development of osteolytic lesions.<\/jats:p>","DOI":"10.3390\/cimb46090552","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T13:38:41Z","timestamp":1724765921000},"page":"9330-9341","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Impact of Modern Bone Markers in Multiple Myeloma: Prospective Analyses Pre and Post-First Line Treatment"],"prefix":"10.3390","volume":"46","author":[{"given":"Vlad Stefan","family":"Pop","sequence":"first","affiliation":[{"name":"Hematology Department, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, 400124 Cluj-Napoca, Romania"},{"name":"Oncology-Hematology Department, Emergency Hospital,  2 Ravensburg Str., 440192 Satu Mare, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4557-5364","authenticated-orcid":false,"given":"Mihaela","family":"Iancu","sequence":"additional","affiliation":[{"name":"Department of Medical Informatics and Biostatistics, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9397-0791","authenticated-orcid":false,"given":"Adrian Bogdan","family":"\u021aigu","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, Institute of Medical Research and Life Sciences\u2014MEDFUTURE, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400337 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anda","family":"Adam","sequence":"additional","affiliation":[{"name":"General Pharmacy, Clinic Emergency Hospital Sibiu, 2-4 Corneliu Coposu Blvd, 550245 Sibiu, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gheorghe","family":"Tomoaia","sequence":"additional","affiliation":[{"name":"Orthopedics and Traumatology Department, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, 400132 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9407-2261","authenticated-orcid":false,"given":"Anca Daniela","family":"Farcas","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania"},{"name":"Cardiology Department, Emergency County Clinic Hospital, 400006 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca Simona","family":"Bojan","sequence":"additional","affiliation":[{"name":"Hematology Department, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, 400124 Cluj-Napoca, Romania"},{"name":"Hematology Department, \u201cProf. Dr. Ioan Chiricuta\u201d Oncological Insitute, 400124 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrada","family":"Parvu","sequence":"additional","affiliation":[{"name":"Hematology Department, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, 400124 Cluj-Napoca, Romania"},{"name":"Hematology Department, \u201cProf. Dr. Ioan Chiricuta\u201d Oncological Insitute, 400124 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1586\/17474086.2015.1021772","article-title":"Optimizing quality of life in multiple myeloma patients: Current options, challenges and recommendations","volume":"8","author":"Maes","year":"2015","journal-title":"Expert. Rev. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1007\/s00520-018-4502-9","article-title":"\u2018It is a journey of discovery\u2019: Living with myeloma","volume":"27","author":"Lane","year":"2019","journal-title":"Support. Care Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.3892\/etm.2021.10764","article-title":"Modern markers for evaluating bone disease in multiple myeloma (Review)","volume":"22","author":"Pop","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41408-021-00432-4","article-title":"Management of patients with multiple myeloma beyond the clinical-trial setting: Understanding the balance between efficacy, safety and tolerability, and quality of life","volume":"11","author":"Terpos","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Kaweme, N.M., Changwe, G.J., and Zhou, F. (2021). Approaches and Challenges in the Management of Multiple Myeloma in the Very Old: Future Treatment Prospects. Front. Med., 8.","DOI":"10.3389\/fmed.2021.612696"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"151173","DOI":"10.1016\/j.soncn.2021.151173","article-title":"Multidisciplinary Professional Roles Addressing Needs in Multiple Myeloma: An Innovative \u2018Virtual\u2019 Pharmacist Surveillance Clinic","volume":"37","author":"Ebied","year":"2021","journal-title":"Semin. Oncol. Nurs."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Du, J.S., Yen, C.H., Hsu, C.M., and Hsiao, H.H. (2021). Management of Myeloma Bone Lesions. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22073389"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"155271","DOI":"10.1016\/j.cyto.2020.155271","article-title":"Cytokine profile in multiple myeloma","volume":"136","author":"Jasrotia","year":"2020","journal-title":"Cytokine"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"155358","DOI":"10.1016\/j.cyto.2020.155358","article-title":"Cytokine profiles in patients with newly diagnosed multiple myeloma: Survival is associated with IL-6 and IL-17A levels","volume":"138","author":"Gu","year":"2021","journal-title":"Cytokine"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Melaccio, A., Reale, A., Saltarella, I., Desantis, V., Lamanuzzi, A., Cicco, S., Frassanito, M.A., Vacca, A., and Ria, R. (2022). Pathways of Angiogenic and Inflammatory Cytokines in Multiple Myeloma: Role in Plasma Cell Clonal Expansion and Drug Resistance. J. Clin. Med., 11.","DOI":"10.3390\/jcm11216491"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1182\/blood-2018-11-852459","article-title":"Myeloma bone disease: From biology findings to treatment approaches","volume":"133","author":"Terpos","year":"2019","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Peng, C., Yang, Q., Kong, X., Sun, Z., Wang, L., and Xiao, L. (2024). Association of lymphocyte subsets and cytokines with bone metabolism: A retrospective, cross-sectional study. BMC Musculoskelet. Disord., 25.","DOI":"10.1186\/s12891-023-07137-8"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_14","unstructured":"R Core Team (2024). R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1002\/cncr.24959","article-title":"Beta-2-microglobulin is an independent predictor of progression in asymptomatic multiple myeloma","volume":"116","author":"Rossi","year":"2010","journal-title":"Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.51520\/2766-5240-5","article-title":"Impact of Serum Albumin and B2-Microglobulin level on 2-Year Overall Survival among Newly Diagnosed Multiple Myeloma Patients: A retrospective Study","volume":"1","author":"Salama","year":"2020","journal-title":"RAS Med. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"854","DOI":"10.2214\/AJR.13.10724","article-title":"Tumor Load in Patients With Multiple Myeloma: \u03b22-Microglobulin Levels Versus Whole-Body MRI","volume":"203","author":"Notohamiprodjo","year":"2014","journal-title":"Am. J. Roentgenol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Banaszkiewicz, M., Ma\u0142yszko, J., Vesole, D.H., Woziwodzka, K., Jurczyszyn, A., \u017b\u00f3rawski, M., Krzanowski, M., Batko, K., Ku\u017aniewski, M., and Krzanowska, K. (2019). New Biomarkers of Ferric Management in Multiple Myeloma and Kidney Disease-Associated Anemia. J. Clin. Med., 8.","DOI":"10.3390\/jcm8111828"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.31557\/apjcc.2019.4.3.77-82","article-title":"Biochemical Characterization of Multiple Myeloma Patients across ISS Stages\u2014A Data Base Workup from a Tertiary Care Hospital in India","volume":"4","author":"Mohammed","year":"2019","journal-title":"Asian Pac. J. Cancer Care"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1080\/10428194.2017.1421757","article-title":"A role for bone turnover markers \u03b2-CrossLaps (CTX) and amino-terminal propeptide of type I collagen (PINP) as potential indicators for disease progression from MGUS to multiple myeloma","volume":"59","author":"Vallet","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1046\/j.1365-2257.2003.00492.x","article-title":"The clinical and prognostic significance of erythrocyte sedimentation rate (ESR), serum interleukin-6 (IL-6) and acute phase protein levels in multiple myeloma","volume":"25","author":"Alexandrakis","year":"2003","journal-title":"Clin. Lab. Haematol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Harmer, D., Falank, C., and Reagan, M.R. (2018). Interleukin-6 Interweaves the Bone Marrow Microenvironment, Bone Loss, and Multiple Myeloma. Front. Endocrinol., 9.","DOI":"10.3389\/fendo.2018.00788"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Lee, C., Oh, J.I., Park, J., Choi, J.H., Bae, E.K., Lee, H.J., Jung, W.J., Lee, D.S., Ahn, K.S., and Yoon, S.S. (2013). TNF \u03b1 mediated IL-6 secretion is regulated by JAK\/STAT pathway but not by MEK phosphorylation and AKT phosphorylation in U266 multiple myeloma cells. BioMed Res. Int., 2013.","DOI":"10.1155\/2013\/580135"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.7314\/APJCP.2016.17.3.1009","article-title":"Effects of TNF\u03b1, NOS3, MDR1 Gene Polymorphisms on Clinical Parameters, Prognosis and Survival of Multiple Myeloma Cases","volume":"17","author":"Basmaci","year":"2016","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1852517","DOI":"10.1155\/2017\/1852517","article-title":"Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma","volume":"2017","author":"Musolino","year":"2017","journal-title":"Mediat. Inflamm."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1835836","DOI":"10.1155\/2020\/1835836","article-title":"Cytokine and Chemokine Profile in Patients with Multiple Myeloma Treated with Bortezomib","volume":"2020","author":"Robak","year":"2020","journal-title":"Mediat. Inflamm."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1023\/A:1008331714186","article-title":"Molecular aspects of multiple myeloma","volume":"11","author":"Kastrinakis","year":"2000","journal-title":"Ann. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Isola, I., Bras\u00f3-Maristany, F., Moreno, D.F., Mena, M.-P., Oliver-Calders, A., Par\u00e9, L., Rodr\u00edguez-Lobato, L.G., Martin-Antonio, B., Cibeira, M.T., and Blad\u00e9, J. (2021). Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.792609"}],"container-title":["Current Issues in Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1467-3045\/46\/9\/552\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:42:48Z","timestamp":1760110968000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1467-3045\/46\/9\/552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,24]]},"references-count":28,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["cimb46090552"],"URL":"https:\/\/doi.org\/10.3390\/cimb46090552","relation":{},"ISSN":["1467-3045"],"issn-type":[{"value":"1467-3045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,24]]}}}